Arthneeti
SMS Pharmaceuticals LtdQ3 FY24

SMS Pharmaceuticals Ltd Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹479P/E: 43.4Market Cap: ₹4.4K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

N/A

Margin

N/A

Fundraise

N/A

Order

N/A

Capex

N/A

0 of 0 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

No information is provided regarding the same in the latest conference call.

See what SMS Pharmaceuticals Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

No information is provided regarding the same in the latest conference call.

See what SMS Pharmaceuticals Ltd management said on order book — free account, 30 seconds.

Capex plans

No information is provided regarding the same in the latest conference call.

Track SMS Pharmaceuticals Ltd — get its next earnings analysis in your feed

How does SMS Pharmaceuticals Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisSMS Pharmaceuticals Ltd
See where SMS Pharmaceuticals Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does SMS Pharmaceuticals Ltd rank in Pharmaceuticals & Biotechnology?

Compare SMS Pharmaceuticals Ltd against every Pharmaceuticals & Biotechnology company (Q3 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Continue your research

What SMS Pharmaceuticals Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Aptus Pharma Ltd (Q4 FY26)

    The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…

  • Aptus Pharma Ltd (Q1 FY27)

    Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…

  • RPG Life Sciences Ltd (Q2 FY25)

    Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.

  • FDC Ltd (Q3 FY23)

    Q3FY23 Revenue from operations: ₹407 crores, up 19% YoY from ₹341 crores in Q3FY22 (Page 13). Key concall takeaways from FDC Ltd's Q3 FY23 earnings call — and…

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →